Publications by authors named "A D Sherry"
Background: Noninferiority (NI) and equivalence trials evaluate whether an experimental therapy's effect on the primary endpoint (PEP) is contained within an acceptable margin compared to standard-of-care. The reliability and impact of this conclusion, however, is largely dependent on the justification for this design, the choice of margin, and the analysis population used.
Methods: A meta-epidemiological study was performed of phase 3 randomized NI and equivalence oncologic trials registered at ClinicalTrials.
Article Synopsis
- Stereotactic body radiation therapy (SBRT) delivers precise, high-dose radiation to tumors, particularly effective in treating genitourinary cancers like prostate and renal cell carcinoma, due to their increased sensitivity to this method compared to traditional radiation.* -
- Advances in radiation planning and imaging have boosted the evidence supporting SBRT's use and its clinical application, leading to ongoing trials and investigations into its efficacy for both localized and metastatic diseases.* -
- Future research will focus on optimizing SBRT techniques, refining treatment indications, and exploring combinations with systemic therapies to enhance treatment effectiveness and improve patients' quality of life.*
Article Synopsis
- Previous research indicated that the MRI probe GdL1 can differentiate between healthy and cancerous prostate tissues based on zinc levels.
- Mice were given varying zinc diets for three weeks, and their prostate zinc secretion was analyzed using advanced imaging techniques.
- Results showed that healthy mice effectively regulated zinc levels, while cancerous mice struggled, suggesting that zinc supplements before imaging could improve prostate cancer detection accuracy.
Article Synopsis
- The study investigates whether adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) in patients with oligometastatic breast cancer.
- A phase II randomized trial, EXTEND, included patients with up to five metastases and compared MDT plus SOC to SOC alone, measuring outcomes such as PFS and overall survival (OS).
- Results from 43 patients showed no significant improvement in PFS or other secondary endpoints with MDT, suggesting it may not provide additional benefit for this patient group, albeit with limitations in study size and sample diversity.
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.
Int J Radiat Oncol Biol Phys
December 2024
Purpose: Increasing data suggest that radiation therapy, particularly ablative radiation therapy, alters the natural history of metastatic disease. For patients with metastatic disease enrolled in prospective trials testing systemic therapy, the use of off-protocol radiation therapy to improve clinical symptoms or extend the duration of study systemic therapy may influence study endpoints. We sought to evaluate how often off-protocol radiation therapy was permitted among systemic therapy phase 3 trials, how often off-protocol radiation therapy is used, and whether off-protocol radiation therapy correlated with study outcomes.
View Article and Find Full Text PDF